Farhan S, Tentzeris I, Freynhofer M K, Vogel B, Huber K
3rd Department of Medicine, Cardiology and Emergency Medicine, Wilhelminenhospital, Vienna, Montleartstr. 37, 1160, Vienna, Austria.
Herz. 2012 May;37(3):264-72. doi: 10.1007/s00059-012-3610-4.
Acute coronary syndrome (ACS) is associated with high mortality even in the acute phase as well as in the post-acute (chronic) phase. Diabetes mellitus type 2 (DM-2), on the other hand, further increases mortality after ACS. Several new antiplatelet and antithrombotic drugs available for clinical use have also been investigated in patients with DM-2, and the guidelines of the European Society of Cardiology (ESC) were recently adapted. However, in daily clinical practice choosing the most suitable regimen is a challenge in many cases. This review article aims to shed light on and simplify antiplatelet and antithrombotic therapy in ACS patients with DM-2 in order to ease the clinician's decision-making.
急性冠状动脉综合征（ACS）即使在急性期以及急性后期（慢性期）都与高死亡率相关。另一方面，2型糖尿病（DM-2）会进一步增加ACS后的死亡率。几种可用于临床的新型抗血小板和抗血栓药物也已在DM-2患者中进行了研究，欧洲心脏病学会（ESC）的指南最近也进行了调整。然而，在日常临床实践中，在许多情况下选择最合适的治疗方案是一项挑战。这篇综述文章旨在阐明并简化DM-2的ACS患者的抗血小板和抗血栓治疗，以方便临床医生做出决策。
